Prothena (PRTA) to Release Earnings on Wednesday

Prothena (NASDAQ:PRTA - Get Free Report) will be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Prothena to post earnings of ($1.21) per share for the quarter.

Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.03). Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. The firm had revenue of $0.32 million during the quarter, compared to analyst estimates of $2.15 million. During the same quarter last year, the firm earned $0.12 earnings per share. Prothena's quarterly revenue was down 99.4% on a year-over-year basis. On average, analysts expect Prothena to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Prothena Price Performance

Shares of NASDAQ:PRTA traded up $0.62 during trading on Thursday, reaching $22.04. The stock had a trading volume of 530,194 shares, compared to its average volume of 741,014. The business's 50-day moving average price is $24.83 and its 200 day moving average price is $31.33. Prothena has a 52 week low of $19.65 and a 52 week high of $79.65. The stock has a market capitalization of $1.18 billion, a PE ratio of -7.87 and a beta of 0.30.

Analysts Set New Price Targets

Several brokerages have recently commented on PRTA. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Prothena in a report on Wednesday, March 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Prothena in a research report on Wednesday, April 10th. Royal Bank of Canada decreased their price objective on Prothena from $36.00 to $35.00 and set a "sector perform" rating on the stock in a research report on Friday, February 16th. StockNews.com downgraded Prothena from a "hold" rating to a "sell" rating in a research report on Monday, February 19th. Finally, Oppenheimer decreased their price target on Prothena from $98.00 to $80.00 and set an "outperform" rating on the stock in a report on Tuesday, February 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $68.14.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.